Stay Ahead with Daily Biotech & HealthTech Innovation Insights
- by Tahir Amin and Rohit Malpani“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.”
- by Brittany TrangCEO of BigHat Biosciences, which designs antibody therapies using machine-learning, on how AI can, and cannot, help in drug development.
- by William Roper, Jeffrey Koplan, Richard Besser, Tom Frieden, Anne Schuchat, Robert Redfield, Rochelle Walensky, and Mandy CohenA State Department plan scheduled to be implemented June 1 would strip the U.S. of decades of disease defense, write eight former CDC directors.
- by Lindsay Stark and Ilana Seff“Women and girls in eastern Congo will be harmed in predictable, named ways over the next 12 months,” write researchers Lindsay Stark and Ilana Seff.
- by Lizzy LawrenceWASHINGTON — People in the food world didn’t know what to expect when the Trump administration appointed a little-known Florida attorney as the FDA’s top food official in 2025. They…
- by Jason MastEli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.
- by Torie Bosch“There's a whole industry that seems to have sprung up”: Two experts on the people profiting from the rise of the perimenopause movement.
- by Tara BannowThe Trump administration disclosed plans to reduce state directed payments even more, setting up a probable showdown with provider groups.
- by Meghana KeshavanMerck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
- by Ed SilvermanBiogen and Denali said their experimental Parkinson’s therapy failed to slow the degenerative brain disorder in a randomized trial
- by Theresa GaffneySeed oil panic, how STIs spread, and more health news from Morning Rounds
- by Allison DeAngelisRetro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it announced Friday.
- by Annalisa MerelliSupporters worry that a men’s health office created by the Trump administration risks being dismantled by a future Democratic president
- by Cole Hanson“My patients are replacing olive oil with beef tallow, even if they don't tell me during cardiac rehab,” writes a clinical dietitian.
- by Risa JampelThis skeptic of AI in medicine sees one place where it could be valuable.
- by Ed SilvermanHow a pharma company is soliciting research that can be used to blunt pharma proposed reforms in Washington.
- by Jessica Bartlett — Boston GlobeThe company behind the analytics, Vizient, touts MGH's increasing hospice enrollment to improved mortality performance.
- by Jason Mast and Matthew HerperBiogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the degenerative brain disorder in a randomized trial.
- by Anil OzaBesides showing skepticism on the budget, senators grilled the NIH director about a leadership vacuum, two viral outbreaks, and the pace of funding.
- by Adam FeuersteinA type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with lung cancer, according to Phase 3…
- Recorded at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with BioAge co-founder and CEO Kristen Fortney on aging biology, inflammation and why BioAge believes its oral NLRP3 inhibitor could have applications across multiple diseases.
- It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in the fast-moving world of cell therapies.
- OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking maintenance use of the combination to improvements over best supportive care.
- A phase 2b trial of Biogen and Denali Therapeutics’ Parkinson’s disease candidate has missed its primary endpoint, prompting the partners to end development in the idiopathic form of the condition.
- by ,Stephen Hahn, M.D., who served as the commissioner of the FDA for just over a year during the first Trump administration, is taking his extensive regulatory expertise to Turn Therapeutics. As executive clinical and regulatory lead, Hahn will guide the regulatory strategy for GX-03, Turn’s topical eczema treatment that is currently in a phase 2 study.
- Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it picked up from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol reductions after a higher dosing regimen.
- According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with Keytruda slashed the risk of disease progression or death by a whopping 65% compared with Keytruda alone in treatment-naïve, PD-L1-positive non-small cell lung cancer.
- As Eli Lilly looks to hold its lead in the lucrative obesity market, the company’s next-gen prospect, the triple-G drug retatrutide, has met the primary endpoint for weight loss in another pivotal study. Though the results show competitive efficacy and tolerability, they may leave some observers slightly underwhelmed based on high expectations.
- Cancer immunotherapy company Liminatus Pharma has agreed to pay out shares worth $320 million to buy CAR-T biotech InnocsAI.
- Infex Therapeutics is pushing ahead with development of a non-cystic fibrosis bronchiectasis drug candidate after posting phase 2a data, advancing efforts to add to the options for treating patients who recently gained access to Insmed’s Brinsupri.
- Several biotech contracts are rotating through Kalshi and Polymarket, while a prediction market specifically focused on clinical trials has recently launched.
- by ,As an outbreak of Ebola in central Africa continues to worsen, the federal government has tapped a little-known biotech in San Diego to provide doses of an experimental antibody that may be used to treat the deadly virus.
- Medtronic has entered a deal to acquire SPR Therapeutics, a Cleveland-based company whose flagship product delivers short-term electrical nerve stimulation for chronic pain patients, for approximately $650 million in cash.
- London-based Global Healthcare Opportunities and Singapore-based CBC Group announced plans to merge, creating what they called the largest healthcare-focused investment manager, with over $21 billion in assets.
- Qiagen, a Netherlands-based diagnostics maker, is linking with tech giant Nvidia in a collaboration aimed at boosting the ability of researchers to leverage AI in the drug discovery process.
- San Carlos-based Engage is developing non-viral DNA delivery systems that aim to overcome traditional limitations associated with the modality.
- In the sprawling metropolis of Houston, a new biotech has emerged to tackle the biology underlying a lung disease that has no clear cause. Oorja Bio launched yesterday afternoon with $30 million and an in-licensed, novel approach to treat idiopathic pulmonary fibrosis.
- BMS is the latest large pharma company to make a major bet on AI, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared intelligence platform” across the drugmaker’s global operations.
- Incyte is paying Genesis $80 million upfront to expand use of its partner’s AI platform across a broader range of targets, continuing the biotech’s rapid embrace of AI in drug discovery and development.
- The big new thing in medtech for 2026 is AI-powered apps and chatbots designed to help patients navigate their laboratory test results. Now, testing giant Labcorp is getting in on the act.
- by Frank VinluanDatroway landed its third FDA approval in the past 18 months, this time as a treatment for triple negative breast cancer. The antibody drug conjugate was developed under a broad collaboration between Daiichi Sankyo and AstraZeneca. The post AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast Cancer appeared first on MedCity News.
- by Katie AdamsA new UPMC report found that while most health systems now offer precision medicine programs, many still face challenges scaling them due to reimbursement, data integration and patient engagement issues. Health system leaders say the field’s future depends on embedding genomics into routine care, as well as proving its clinical and financial value. The post Precision Medicine’s Next Hurdle Isn’t Science — It’s Execution appeared first on MedCity News.
- by Jonathan TreiberIs a private-label product really better once you factor in performance, durability, and everything it takes to support it? Sometimes yes and sometimes no. The job is knowing the difference. The post Maximizing Value vs. Minimizing Cost in Healthcare Purchasing appeared first on MedCity News.
- by David KirkThe takeaway from the current failure of wearables is that signal without synthesis doesn’t change outcomes. If healthcare treats AI as just another way to collect or repackage data, it will repeat the same mistake. The post What the Failure of Wearables Can Teach Us About AI appeared first on MedCity News.
- by Scott ChethamWhen coordinators are buried in documentation, scheduling, and data reconciliation, patient engagement is the first thing to go. And when engagement drops, retention drops with it. The post Clinical Operations Burnout Is Undermining Patient Enrollment appeared first on MedCity News.
- by Steve MongelliThe defining capability of modern health plans is intelligent engagement with unified infrastructure. The post Smarter Engagement for Stronger Growth: How Payers Can Successfully Do More with Less appeared first on MedCity News.
- by Mike BartonAI genuinely could reduce barriers, by making health information more conversational, more personalized, and easier to act on. But that only happens if the people building these tools decide, from day one, that accessibility isn’t optional. The post AI Is Becoming the Front Door to Healthcare — But Millions of Patients Can’t Get Through It appeared first on MedCity News.
- by Sage KhanujaA newly diagnosed person experiences healthcare as a complicated maze of physicians, specialists, pharmacies, insurers, deductibles, formularies, prior authorizations, benefit explanations and coverage rules that rarely speak to one another and often contradict each other. Better AI can help. The post AI Made Healthcare Smarter – The Next Step is Making It Simpler appeared first on MedCity News.
- by Katie AdamsThree health systems — Mount Sinai, Michigan Medicine and the University of Kansas Health System — are suing CVS Health, alleging its pharmacy benefit manager diverted roughly $250 million in savings from the 340B program through “spread pricing” between 2020 and 2025. The post Hospitals Take CVS to Court Over Alleged $250M 340B Scheme appeared first on MedCity News.
- by Frank VinluanPharmacies and wholesalers claimed Takeda Pharmaceutical delayed generic competition from entering the market, forcing them to overpay for a gastrointestinal drug. Takeda said the trial had “evidentiary and legal errors,” and the company will appeal the verdict. The post Takeda Vows Appeal of $885M Jury Verdict in ‘Pay-for-Delay’ Antitrust Case appeared first on MedCity News.
- by Arundhati ParmarSelective contracting, use of AI, networking volatility and interest in value-based care are some of the larger trends affecting the dental and vision benefits market. The post What Trends Are Shaping the Dental and Vision Benefits Market? appeared first on MedCity News.
- by Aaron NollWhen awareness is timely, aligned, and delivered through trusted channels, such as EHR systems or digital media, it strengthens every step of the patient journey, especially understanding potential options such as ground-breaking clinical trials or targeted diagnostic testing. The post Timing Meets Context: Aligning Patients and Providers with AI-Enabled Omnichannel Engagement appeared first on MedCity News.
- by Avinash MaddineniWhen structured oversight meets practical innovation, the result is systems that are not only technically sound but actually usable. The post AI in Digital Health, From Early Detection to Responsible Deployment appeared first on MedCity News.
- by Avi PhilipsonAs demand for long-term care rises, workforce stability is no longer just an operational concern. It is increasingly a direct measure of care quality itself. Organizations that fail to recognize this shift risk undermining both outcomes and access. The post Workforce of the Future: Supporting Frontline Heroes appeared first on MedCity News.
- by Katie AdamsHealthcare providers and researchers are warning that HHS Secretary Robert F. Kennedy Jr.’s firing of two USPSTF vice chairs could politicize one of the nation’s most influential preventive care panels. The post Providers Sound Alarm After RFK Jr. Fires Top USPSTF Leaders appeared first on MedCity News.
- by Marissa PlesciaEmployer advocates said Cost Plus Wellness could help spur more direct contracting and transparency in healthcare, though they questioned whether the model can scale and adequately measure provider quality and outcomes. The post Will Mark Cuban’s Cost Plus Wellness Appeal to Employers? appeared first on MedCity News.
- by Frank VinluanEli Lilly’s retatrutide set a high mark in weight loss for obesity drugs, but with clinical trial results that show some new side effects. More detailed data from the Phase 3 study are scheduled for presentation next month during the American Diabetes Association Scientific Sessions meeting. The post Eli Lilly’s Triple Combo Obesity Drug Tops 28% Weight Loss in a Pivotal Trial appeared first on MedCity News.
- by Muthu RajuOrganizations that focus on execution will reduce variability, improve cash flow, and build resilience against ongoing industry pressure. They will also be better positioned to integrate future innovations as healthcare continues to evolve. The post RCM Has an Execution Problem, Not an Effort Problem appeared first on MedCity News.
- by Scott H. SchnellIf we focus only on placement, we will continue to see cycles of progress and regression. If we focus on stability — on what happens after the keys are handed over — we have an opportunity to change those trajectories more permanently. The post Medicaid’s Housing Problem Isn’t Placement — It’s What Happens Next appeared first on MedCity News.
- by Jost-Vincent SteiskalWhen clinics select an AI partner – especially for AI Voice Agents – the expectation is that the tool gets the job done. Without integration into your systems and workflows, that rarely happens. Clinics end up with an incomplete solution that never adds the expected value and fails at the exact use cases AI should be best at. The post Why AI Fails in Healthcare Clinics (And What Actually Works) appeared first on MedCity News.
